Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

Boster Bio is also a leading manufacturer of the Western blot test, a critical service that complements its extensive IHC and ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Ziihera (zanidatamab-hrii) for the treatment of adults with previously treated, unresectable or metastatic HER2-positive ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...

Intermountain Healthcare initiated an IHC-based LS screening program in 2009. We were also concerned about the issues of consent and in the fall of 2008 convened a national advisory group that ...

The availability of a simple immunohistochemical (IHC) test for HER2-low status is seen as critical to the successful rollout of Enhertu (trastuzumab deruxtecan) in this category of breast cancer ...

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...